Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dfriz
- Development stage
- Unknown
- Lead developer
- Sinsan Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Dfriz** is an oral fixed-dose combination tablet marketed by Sinsan Pharmaceuticals for **osteoarthritis**. It contains diacerein 50 mg, glucosamine 750 mg, and methylsulfonylmethane 250 mg. Diacerein is a symptomatic slow-acting osteoarthritis drug whose active metabolite rhein is associated with suppression of interleukin-1-mediated inflammatory and cartilage-degrading processes; glucosamine supports proteoglycan and cartilage-matrix synthesis; and methylsulfonylmethane is included for supportive anti-inflammatory and joint-symptom management. ([1mg.com](https://www.1mg.com/drugs/dfriz-750mg-50mg-250mg-tablet-427325))
- Brand names
- Dfriz
- Other names
- diacerein + glucosamine + methylsulfonylmethane
02
Targets
IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Dfriz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dfriz.